Safety and Efficacy of Intermittent Intravenous Administration of High-Dose XXXX .

@entity1331 @entity1 @entity8 @entity137 @entity409 @entity3052 @entity1778 @entity5626 @entity364 @entity8201
BACKGROUND:    The use of mold-active @entity8201 for antifungal prophylaxis after allogeneic @entity8 ( @entity8 ) is hindered by adverse events and drug-drug interactions. Higher doses of @entity5626 administered intermittently may be an alternative in this setting. METHODS:    This was a single-center, observational 5-year study to characterize the safety and efficacy of intermittent administration of high-dose intravenous @entity1331 (>= 5 doses of >= 300 mg @entity1331 2-3 times weekly) in @entity1 with @entity3052 and allogeneic @entity8 recipients. RESULTS:    A total of 104 @entity1 (84 allogeneic @entity8 recipients and 20 @entity1 with @entity1778 ) received intermittent high-dose intravenous @entity1331 , 83 (79.8%) as prophylaxis. Large variability in the @entity1331 dosing regimen was observed; 78 (75%) @entity1 received >75% of their course as 300 mg @entity1331 3 times weekly. Liver function tests decreased from baseline to end of treatment (EOT; P < .001). @entity1 with normal baseline liver function (n = 55 [52%]) maintained similar enzyme levels throughout the study. For @entity1 with abnormal baseline liver function (n = 49 [47%]), liver function tests significantly improved from baseline to EOT (P  <= .005). Duration and/or @entity1331 dosing algorithms were not associated with liver @entity137 at EOT. There were no significant changes in renal function, and infusion-related reactions or deaths were not observed. Five of 83 (6.0%) @entity1 in the prophylaxis group developed a breakthrough @entity364 . CONCLUSIONS:    In this largest cohort of @entity1 to date, intermittent administration of high-dose @entity1331 was well tolerated, without any associated @entity409 , and may be considered an alternative antifungal prophylactic strategy. Prospective studies are needed to further validate these findings.
